riboflavin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
riboflavin — decreases diastolic blood pressure (setting unspecified)
Evidence strength: very limited.Finding“Riboflavin supplementation (administered in 2004 and 2008) produced an overall decrease in systolic (-9.2 ± 12.8 mm Hg; P = 0.001) and diastolic (-6.0 ± 9.9 mm Hg; P = 0.003) BP.”
Quoted verbatim from Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up.. - Study
- crossover
- Duration
- 4 months
- Dose
- 1.6 mg/d for 16 wk
- Population
- Patients with the MTHFR 677TT genotype (n = 31 of 83 follow-up participants), crossover in which the 2004 treatment groups were reversed; effect pooled over the 2004 and 2008 interventions
Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: a 4-y follow-up.2012PMID:2227755610.3945/ajcn.111.026245Permalink
To cite this finding: https://catalystproject.ai/e/01M5MC9B87GSB2HNWCSWJCKGKY